肝细胞癌的免疫疗法：从基础研究到临床应用。
Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.
作者信息
Hong Yu-Peng, Li Zi-Duo, Prasoon Pankaj, Zhang Qi
机构信息
Yu-Peng Hong, Department of Oncology, Zhejiang Provincial People's Hospital, Hangzhou 310014, Zhejiang Province, China.
出版信息
World J Hepatol. 2015 May 8;7(7):980-92. doi: 10.4254/wjh.v7.i7.980.
Abstract
Hepatocellular carcinoma (HCC) is a common cancer worldwide with a poor prognosis. Few strategies have been proven efficient in HCC treatment, particularly for those patients not indicated for curative resection or transplantation. Immunotherapy has been developed for decades for cancer control and is attaining more attention as a result of encouraging outcomes of new strategies such as chimeric antigen receptor T cells and immune checkpoint blockade. Right at the front of the new era of immunotherapy, we review the immunotherapy in HCC treatment, from basic research to clinical trials, covering anything from immunomodulators, tumor vaccines and adoptive immunotherapy. The mechanisms, efficacy and safety as well as the approach particulars are unveiled to assist readers to gain a concise but extensive understanding of immunotherapy of HCC.
摘要
肝细胞癌（HCC）是一种全球常见的癌症，预后较差。在HCC治疗中，很少有策略被证明是有效的，特别是对于那些不适合进行根治性切除或移植的患者。免疫疗法已发展了数十年用于癌症控制，并且由于嵌合抗原受体T细胞和免疫检查点阻断等新策略取得了令人鼓舞的成果而受到越来越多的关注。在免疫疗法新时代的前沿，我们回顾了HCC治疗中的免疫疗法，从基础研究到临床试验，涵盖免疫调节剂、肿瘤疫苗和过继性免疫疗法等各个方面。揭示其机制、疗效、安全性以及方法细节，以帮助读者对HCC免疫疗法有一个简洁而全面的了解。
相似文献
1
Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.肝细胞癌的免疫疗法：从基础研究到临床应用。
World J Hepatol. 2015 May 8;7(7):980-92. doi: 10.4254/wjh.v7.i7.980.
2
Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.肝细胞癌：进展机制与免疫治疗。
World J Gastroenterol. 2019 Jul 7;25(25):3151-3167. doi: 10.3748/wjg.v25.i25.3151.
3
Immunotherapy for hepatocellular carcinoma.肝细胞癌的免疫疗法
Drug Discov Ther. 2015 Oct;9(5):363-71. doi: 10.5582/ddt.2015.01054.
4
Immunotherapy Updates in Advanced Hepatocellular Carcinoma.晚期肝细胞癌的免疫治疗进展
Cancers (Basel). 2021 Apr 30;13(9):2164. doi: 10.3390/cancers13092164.
5
Potentiality of immunotherapy against hepatocellular carcinoma.免疫疗法治疗肝细胞癌的潜力。
World J Gastroenterol. 2015 Sep 28;21(36):10314-26. doi: 10.3748/wjg.v21.i36.10314.
6
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.从基础到临床：肝癌的肿瘤免疫微环境和当前免疫治疗策略。
J Exp Clin Cancer Res. 2019 Sep 9;38(1):396. doi: 10.1186/s13046-019-1396-4.
7
Cellular based treatment modalities for unresectable hepatocellular carcinoma.不可切除肝细胞癌的细胞治疗方式
World J Clin Oncol. 2021 May 24;12(5):290-308. doi: 10.5306/wjco.v12.i5.290.
8
Adoptive cell transfer therapy for hepatocellular carcinoma.过继细胞转移疗法治疗肝细胞癌。
Front Med. 2019 Feb;13(1):3-11. doi: 10.1007/s11684-019-0684-x. Epub 2019 Jan 18.
9
[Strategies and challenges of immunotherapy for hepatocellular carcinoma].[肝细胞癌免疫治疗的策略与挑战]
Zhonghua Gan Zang Bing Za Zhi. 2020 Jun 20;28(6):457-460. doi: 10.3760/cma.j.cn501113-20200602-00288.
10
Application of Immunotherapy in Hepatocellular Carcinoma.免疫疗法在肝细胞癌中的应用。
Front Oncol. 2021 Aug 26;11:699060. doi: 10.3389/fonc.2021.699060. eCollection 2021.
引用本文的文献
1
DNA methylation-driven genes in hepatocellular carcinoma patients: insights into immune infiltration and prognostic implications.肝细胞癌患者中DNA甲基化驱动的基因：对免疫浸润及预后意义的见解
Front Med (Lausanne). 2025 Apr 28;12:1520380. doi: 10.3389/fmed.2025.1520380. eCollection 2025.
2
Immune regulation and therapeutic application of T regulatory cells in liver diseases.调节性 T 细胞在肝脏疾病中的免疫调节和治疗应用。
Front Immunol. 2024 Mar 20;15:1371089. doi: 10.3389/fimmu.2024.1371089. eCollection 2024.
3
Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma.肝细胞癌坏死性凋亡相关长链非编码RNA预后特征的构建与验证
Front Genet. 2022 Aug 30;13:916024. doi: 10.3389/fgene.2022.916024. eCollection 2022.
4
Adjuvant therapy using -expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study.使用γ-扩增的同种异体自然杀伤细胞对乙型肝炎病毒相关孤立性肝细胞癌肝切除患者进行辅助治疗：MG4101研究
Ann Hepatobiliary Pancreat Surg. 2021 May 31;25(2):206-214. doi: 10.14701/ahbps.2021.25.2.206.
5
Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.基于免疫检查点抑制剂（ICI）的晚期肝癌联合治疗的最新进展与未来展望
Cancers (Basel). 2021 Apr 18;13(8):1949. doi: 10.3390/cancers13081949.
6
Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.根治性切除术后肝细胞癌的辅助治疗策略。
Front Med. 2021 Apr;15(2):155-169. doi: 10.1007/s11684-021-0848-3. Epub 2021 Mar 23.
7
Cytolytic Activity of Effector T-lymphocytes Against Hepatocellular Carcinoma is Improved by Dendritic Cells Pulsed with Pooled Tumor Antigens.树突状细胞负载肿瘤抗原对效应 T 淋巴细胞杀伤肝癌细胞活性的影响
Sci Rep. 2019 Nov 27;9(1):17668. doi: 10.1038/s41598-019-54087-0.
8
Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review.非肝硬化肝脏与肝癌预后不良相关：文献综述。
Med Sci Monit. 2019 Sep 3;25:6615-6623. doi: 10.12659/MSM.915722.
9
Systems Challenges of Hepatic Carcinomas: A Review.肝癌的系统挑战：综述
J Clin Exp Hepatol. 2019 Mar-Apr;9(2):233-244. doi: 10.1016/j.jceh.2018.05.002. Epub 2018 May 17.
10
HMQ-T-B10 induces human liver cell apoptosis by competitively targeting EphrinB2 and regulating its pathway.HMQ-T-B10 通过竞争性靶向 EphrinB2 并调节其通路诱导人肝细胞凋亡。
J Cell Mol Med. 2018 Nov;22(11):5231-5243. doi: 10.1111/jcmm.13729. Epub 2018 Sep 14.
本文引用的文献
1
Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis.对 CXCL12-CXCR4 轴在肝细胞癌发生中的作用的见解。
Am J Transl Res. 2014 Jul 18;6(4):340-52. eCollection 2014.
2
Roles for chemokines in liver disease.趋化因子在肝脏疾病中的作用。
Gastroenterology. 2014 Sep;147(3):577-594.e1. doi: 10.1053/j.gastro.2014.06.043. Epub 2014 Jul 25.
3
MiR-221 accentuates IFN׳s anti-HCV effect by downregulating SOCS1 and SOCS3.微小RNA-221通过下调细胞因子信号转导抑制因子1和细胞因子信号转导抑制因子3来增强干扰素的抗丙型肝炎病毒效应。
Virology. 2014 Aug;462-463:343-50. doi: 10.1016/j.virol.2014.06.024. Epub 2014 Jul 12.
4
A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma.细胞因子诱导的杀伤细胞疗法联合微创治疗肝细胞癌的荟萃分析。
Clin Res Hepatol Gastroenterol. 2014 Oct;38(5):583-91. doi: 10.1016/j.clinre.2014.04.010. Epub 2014 Jun 9.
5
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.肝细胞癌中的免疫检查点阻断：当前进展与未来方向
Hepatology. 2014 Nov;60(5):1776-82. doi: 10.1002/hep.27246. Epub 2014 Sep 26.
6
GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.GPC3 DNA疫苗在小鼠体内引发针对肝癌的强大细胞抗肿瘤免疫。
Hepatogastroenterology. 2014 Mar-Apr;61(130):278-84.
7
Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells.白细胞介素-37介导肝细胞癌的抗肿瘤活性：CD57⁺自然杀伤细胞的作用
Sci Rep. 2014 Jun 5;4:5177. doi: 10.1038/srep05177.
8
The effects of the CCR6/CCL20 biological axis on the invasion and metastasis of hepatocellular carcinoma.CCR6/CCL20生物轴对肝细胞癌侵袭和转移的影响
Int J Mol Sci. 2014 Apr 16;15(4):6441-52. doi: 10.3390/ijms15046441.
9
Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients.两名肝细胞癌患者的甲胎蛋白DNA初免和腺病毒加强免疫
J Transl Med. 2014 Apr 5;12:86. doi: 10.1186/1479-5876-12-86.
10
Tumor markers for hepatocellular carcinoma.肝细胞癌的肿瘤标志物
Mol Clin Oncol. 2013 Jul;1(4):593-598. doi: 10.3892/mco.2013.119. Epub 2013 May 13.
Zotero 插件